Prostate cancer is one of deadliest cancers in the universe especially in Africa. A lot of work has been done on the treatment and control of breast cancer, colon/colorectal cancer, skin cancer, etc. Only a few works on prostate cancer has been published in literature. The conventional method of treatment used is almost not affordable by many cancer patients due to high cost of drugs and therapy. Also, the cumulative side effects arising from the treatment is enormous to patients. Hence, there is need to exploit local herbs that contain active anticancer ingredients that are readily available and affordable with little or no side effects. The present review was carried out to evaluate published works on medicinal plant species used for treatment and control of prostate cancer in Africa for twenty years . A total number of 48 plant species with 40 families were retrieved from database using ScienceDirect, Google scholar, Web of Science, Springerlink, Scopus, PubMed, and BioMed. All the plant species were reported to possess cytotoxic activity against prostate cancer cell lines in vitro and in vivo. The most cited plant species according to literature sources are Hypoxis hemerocallidea, Plumbago zeylanica, Gongronema latifolium and Mangifera indica. Plant families that were used more in treating prostate cancer were Apocynaceae, Fabaceae, Asteraceae, Cucurbitaceae, Bignoniaceae, Lamiaceae. We conclude that more research be carried out on the medicinal plants' usage on the treatment of prostate cancer and further bio-prospecting drugs from the enlisted plants should explored by the pharmaceuticals in Africa.

Coronavirus disease (COVID-19) has had devastating impacts on the global economy and public health. This study aimed to assess the level of COVID-19 vaccine acceptance, hesitancy, and associated factors among staff and students of the Federal University of Health Sciences Otukpo, Benue State, Nigeria. A web-based cross-sectional survey was conducted between November 2021 and April 2022, and data were collected and analyzed using descriptive and inferential statistics. Of the 150 completed and analyzed questionnaires, the majority of respondents (80.0%) were between 16 and 45 years old. The study found that 58.4% of participants indicated vaccine hesitancy, with skepticism about the vaccine's fast production/rollout and fear of vaccine side effects being the most common reasons for hesitation. Respondents' age, religion, and category were significant factors influencing vaccine acceptance and hesitancy (P < 0.05). The university community has a high level of awareness of COVID-19 but low vaccine acceptance, resulting in high levels of vaccine hesitancy. The study recommends that policymakers and public health officials should prioritize testing and vaccination for job categories with higher risk of exposure to COVID-19. They should provide accurate information about COVID-19 testing and vaccination and implement workplace-based testing and vaccination programs. These interventions can help to increase COVID-19 testing and vaccination uptake among the university community and mitigate the spread of COVID-19.